Inflammatory bowel disease first step assay system
US6218129A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 15, 1998 |
| Grant date | Apr 17, 2001 |
| Priority date | — |
| Expiry date | May 15, 2018 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/065
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a highly sensitive method of diagnosing inflammatory bowel disease (IBD) in an individual. The method includes the steps of isolating a sample from the individual; determining by non-histological means whether the sample is positive for anti-neutrophil cytoplasmic antibodies (ANCA); determining whether the sample is positive for anti-Saccharomyces cerevisiae immunoglobulin A (ASCA-IgA); determining whether the sample is positive for anti-Saccharomyces cerevisiae immunoglobulin G (ASCA-IgG); and diagnosing the individual as having IBD when the sample is positive for ANCA, ASCA-IgA or ASCA-IgG, and diagnosing the individual as not having IBD when the sample is negative for ANCA, ASCA-IgA and ASCA-IgG, provided that the method does not include histological analysis of neutrophils.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.